Disability

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),…

3 years ago

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with…

3 years ago

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),…

3 years ago

“Modern Miracles”: ReWalk Technology Showcased at the Hanukkah Celebration Hosted by the Embassy of the State of Israel to Belgium and Luxembourg in Antwerp

ReWalk Robotics, Ltd. is honored to have presented its technology at the prestigious Modern Miracles Celebration with the Embassy of…

3 years ago

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Updated Interim Results for the Six Months Ended 30 June 2022

LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS…

3 years ago

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Interim Results for the Six Months Ended 30 June 2022

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022…

3 years ago

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated…

3 years ago

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

DMPK Transcript Levels Figure 1. No significant changes in mean DMPK transcript levels were observed in DM1 patient cells or…

3 years ago